Material Event (Form 8-K)

As previously disclosed on February 12, 2026, the Audit Committee of the Board of Directors of Organon & Co. (the "Company") conducted an independent review of the information brought to the Audit Committee's attention on February 11, 2026 relating to the timing of the Company's purchases of biosimilars from a supplier in prior years. The Audit Committee has completed its independent review with the assistance of outside counsel. The review determined that no action is required.

The independent review did not find evidence of improper conduct related to the transactions in question and did not identify any matters requiring adjustments to the Company's previously issued financial statements or disclosures in its filings with the Securities and Exchange Commission (the "SEC"). The Company intends to timely file its Form 10-K for the year ended December 31, 2025.